View source for CT Angiography Biomarker Ctte

'''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
'''Secretary''': Julie Lisiecki
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]

==Meetings==

'''Recent Call Summaries:'''

*[[Media: 2019 04 08 QIBA CT Angiography_FINAL-b.pdf | April 81, 2019]]
*[[Media: 2019 03 11 QIBA CT Angiography_FINAL-b.pdf | March 11, 2019]]
*[[Media: 2019 02 25 QIBA CT Angiography_FINAL.pdf | February 25, 2019]]
*[[Media: 2019 02 11 QIBA CT Angiography_FINAL.pdf | February 11, 2019]]
*[[Media: 2019 01 28 QIBA CT Angiography_FINAL.pdf | January 28, 2019]]
*[[Media: 2019 01 14 QIBA CT Angiography_FINAL.pdf | January 14, 2019]]
*[[Media: 2018 12 17 QIBA CT Angiography_FINAL.pdf | December 17, 2018]]

'''''[[CT Angiography Call Summaries Archive]]'''''

==Project Snapshot - CT Angiography==
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA). 

Excerpt from the biomarker committee submission form:

The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA).  The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.

==Profile Development==

*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-26.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 26, 2019]]
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-11.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 11, 2019]]
*[[Media:2019_01-31_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 31, 2019]]
*[[Media:2019_01-14_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 14, 2019]]
*[[Media:2018_12-17_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | December 17, 2018]]

'''''[[Atherosclerosis Biomarkers Profile Draft Archive]]'''''

==Groundwork Projects==

==Reference Materials==
*[[Media:Biomarkers Selection Criteria.pdf | QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler}]] ''March 27, 2018'' (PDF)

==Conformance Materials==